Cancer is a predicament these days and the need to come up with drugs to solve the problem is essential. Dr. Clay Siegall has made efforts to come up with the solution. In 1998, he created a company that has manufactured drugs that cure cancer. The Seattle Genetics is the company that he formed and serves as the president, chief executive officer, and chairman. Under his leadership, Seattle Genetics has been able to come up with cancer therapies. ADCETRIS was boosted with the support of the US Food and Drug Administration that has helped in the creation of new cancer drugs.
He is an interactive individual too, and in his blogging website, he writes about the current affairs in the USA and the rest of the world. Clay also writes about general topics like for example ‘Cracking The Code That Lets The Brain ID Any Face Fast.’ and studies that have been carried out about the space. Recently he wrote about Trump getting out of the Paris Climate Change deal, how an energy economist see that the exit from the Paris deal has a little effect on the US. There are several other topics that he contributes to that are interactive and helpful.
Dr. Siegall has a BS in Zoology from the University of Maryland and a Ph. D in genetics from the George Washington University. Clay Siegall has been instrumental in developing the first FDA-approved antibody (Ab) drug and 20 other drugs. Seattle Genetics partners with Bayer, Pfizer, and Genentech.
According to him, it is possible to eliminate chemotherapies and replace them with workable drugs that will cure cancer. These alternatives will be accurate and will target the dead, malignant and zombie cells curing cancer without affecting the healthy cells. He has been interested in medicine since he was young. His aim was to give hope to the patients who were hopeless.
Profits that Seattle Genetics get come from partnerships with other budding companies that are not licensed. They also help the small businesses with technologies and unique processes. ADCETRIS exclusivity is also a revenue and profit earner for the enterprise.